project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9MC; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.79; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.45; rna integrity number: 8.0; age at index: 69; days to birth: -25477; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1943; age at diagnosis: 25477; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 455.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 434; initial weight: 230.0; sample id: 5c19c643-d935-46bd-b7b9-1e2f2342af28; sample submitter id: TCGA-ZG-A9MC-01A; portion id: 33499b92-acd4-420c-8dd8-d23406e1c864; portion submitter id: TCGA-ZG-A9MC-01A-31; slide id: 49832d2f-419b-4aaa-9930-d7e37ad32a42; slide submitter id: TCGA-ZG-A9MC-01A-03-TSC; percent lymphocyte infiltration: 40.0; percent monocyte infiltration: 20.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 40.0; percent tumor cells: 60.0; percent tumor nuclei: 60.0; section location: TOP;